Esketamine (Spravato®) in combination with a SSRI or SNRI is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current depressive episode.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||16/12/2019|
|Rapid review completed||10/02/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of esketamine compared with the current standard of care.|